Effect of Zinc Supplementation on Morbidity due to Acute Diarrhoea in Infants and Children in Sanaa, Yemen: A randomized controlled double blind clinical trial.

OBJECTIVES: To study the impact of zinc administration on the morbidity and mortality attributed to diarrhoea among children less than 5 years old. METHODS: The study design was a randomized double blinded controlled clinical trial, held at Elsabeen Hospital for Maternity and Childhood, Sana'a, Yemen. The study was conducted during the period September 2005 to October 2006 on 180 children less than 5 years old with acute diarrhoeal episodes. They were randomly allocated to two groups; one of them received a placebo and the other received zinc acetate syrup for 14 days. Both groups were followed up for 2 months. RESULTS: ZINC WAS ABLE TO DECREASE THE MEAN NUMBER OF DIARRHOEAL EPISODES: 1.39 in the intervention group versus 2.59 in the control group. It also reduced the mean frequency of stools per day in each attack (3.57 in the intervention group versus 5.47 in the control group) and the volume of stool in each attack during the follow-up period. Moreover, zinc was significantly more palatable. CONCLUSION: We can conclude from the study that administration of zinc for two weeks during acute diarrhoeal episodes could decrease the incidence of further diarrhoeal episodes as well as the severity of these episodes. The lower rates of child morbidity with zinc treatment represent substantial benefits from a simple and inexpensive intervention that can be incorporated in existing efforts to control diarrhoeal disease.

Evaluation of the role of postnatal ambroxol in the prevention and treatment of respiratory distress syndrome in preterm neonates.

OBJECTIVE: to study the effect of the postnatal administration of Ambroxol in the prevention of respiratory distress syndrome in preterm neonates at risk and on the severity of the disease in those neonates already suffering from it. METHODS: the study was a randomized clinical trial performed on 120 preterm neonates admitted to the neonatal unit of the Suez Canal University Hospital, Egypt, with gestational age of 28 to 34 weeks. It was performed in the period from September 2001 through March 2003. Half of the enrolled neonates received intravenous ambroxol (20 mg/kg/d), while the control group received the routine management of prematurity and a placebo. RESULTS: Ambroxol decreased the incidence of Respiratory Distress Syndrome (RDS), improved the gas exchange, and decreased Continious Positive Airway pressure (CPAP) pressure, the length of mechanical ventilation and also the mortality rate. CONCLUSION: the study concluded that Ambroxol reduced the incidence of this disease in preterm neonates at risk of developing it, and improved the clinical course of RDS.